Search Results

96 results

  1. CORESTA Congress, Kunming, 2018, Agronomy/Phytopathology Groups, APPOST 30

    Nicotine reduction and consumer perception: a scientific approach for quantifying possible impact of low nicotine cigarettes on consumer behaviour

    GUO Mengran(1); VERRON T.(1); DORLHAC de BORNE F.(2); PRITCHARD J.(3); COLARD S.(1)
    (1) SEITA - Imperial Brands plc, Paris, France; (2) Imperial Tobacco Limited, Leaf Research, Bergerac, France; (3) Imperial Brands, Bristol, U.K.
    In 2015, the WHO Study Group on Tobacco Product Regulation (TobReg) issued an advisory note recommending a strategy to reduce nicotine in tobacco to levels which would not be sufficient to lead to the development and/or maintenance of addiction. In the US ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 33 (also presented at TSRC 2018)

    Comparison of potential health risks of combustible, heat-not-burn, and electronic cigarettes

    LIU C.; MARANO K.
    RAI Services Company, Winston-Salem, NC, U.S.A.
    Given U.S. Food and Drug Administration (FDA) regulation of tobacco products via the Family Smoking Prevention and Tobacco Control Act, there is a growing recognition of the need for evidence to assist both applicants and the FDA in making determinations ...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 35

    Different population modeling approaches lead to directionally similar conclusions about the potential for tobacco harm reduction

    BACHAND A.(1); SULSKY S.(1); CURTIN G.(2)
    (1) Ramboll U.S. Corp., Amherst, MA, U.S.A.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    There are a number of dynamic population models that can be used to quantify the overall population health effects of beneficial and/or harmful changes in tobacco use patterns. These models can be broadly categorized as either following a single birth ...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 36 (also presented at TSRC 2018)

    Multi-dimensional tipping point analyses: Assessing simultaneous shifts in tobacco use patterns from a higher to a lower risk product

    BACHAND A.(1); SULSKY S.(1); CURTIN G.(2)
    (1) Ramboll U.S. Corp., Amherst, MA, U.S.A.; (2) RAI Services Co., Winston-Salem, NC, U.S.A.
    The Dynamic Population Modeler (DPM(+1)) employs a birth cohort framework to estimate effects on population mortality if tobacco use patterns shift from a higher- to lower-risk product. DPM(+1) allows for evaluation of changes in use patterns within the ...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 52 (also presented at TSRC 2018)also presented at TSRC 2018)

    Consumers’ perceptions of disease-specific modified-risk claims are best evaluated in a disease-specific manner

    SHIFFMAN S.(1); CURTIN G.(2)
    (1) Pinney Associates, Pittsburgh, PA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.
    Manufacturers seeking to make claims about modified-risk tobacco products (MRTPs) must assess consumers' perceptions of risk reduction for these products. Claims made for the MRTP and assessment of perceived risk reduction can be global (e.g. &quot ...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 53 (also presented at TSRC 2018)

    Comparing direct and indirect assessments of perceptions of reduced risk for a modified-risk tobacco product

    SHIFFMAN S.(1); CURTIN G.(2)
    (1) Pinney Associates, Pittsburgh, PA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.
    Manufacturers seeking to make claims about modified-risk tobacco products (MRTPs) must assess consumers' perceptions of absolute and relative risks for these products. We cross-validate data from two methods: (a) indirect assessments based on the ...
  7. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful exposure ...